Global Health Progress (GHP) is pleased to highlight the announcement that the not-for-profit public-private partnership Medicines for Malaria Venture (MMV) became the first product development partnership (PDP) to contribute intellectual property to The Pool for Open Innovation against Neglected Tropical Diseases (The Pool).
MMV joined GlaxoSmithKline (GSK), Alnylam Pharmaceuticals, and the Massachusetts Institute of Technology (MIT) in providing intellectual property to The Pool. Discussing the decision, Professor Patrick Nef, Executive Vice President of Business Development at MMV, states, 'In this way we hope to make fully available the know-how and technologies, assembled by MMV against malaria, for the research and development of innovative and efficacious treatments for other neglected diseases.”
By emphasizing a more accessible approach to intellectual property and know-how, The Pool facilitates access to patents and/or technologies for organizations that want to conduct research on treatments and motivates innovative and efficient drug discoveries and developments for neglected diseases.
The Pool is administered by BIO Ventures for Global Health (BVGH). It’s accessible to industry, non-profit institutions, and academic researchers who conduct research and drug development activities that deliver real benefits for patients in the least developed countries of the world.
Global Health Progress echoes the sentiment that MMV's contribution of patents to The Pool, resulting from its research for new antimalarials, is an important milestone from an organization that plays a major role in leading the development of new therapeutics for malaria.
Global Health Progress supports the continuing partnership between not-for-profit public-private partnerships and research-based biopharmaceutical companies as a way to fight neglected tropical disease through targeted research and development (R&D), improving access to critical medicines and providing key intellectual property.Global Health Progress supports the continuing partnership between not-for-profit public-private partnerships and research-based biopharmaceutical companies as a way to fight neglected tropical disease through targeted research and development (R&D), improving access to critical medicines and providing key intellectual property.
Global Health Progress supports efforts to raise awareness & mobilize resources to address health challenges, such as neglected tropical diseases, in the developing world & bringing leaders together with international health experts, the pharmaceutical industry, governments & the private sector.
Read More From Mark Grayson
|
